NuCana plc (NASDAQ:NCNA – Get Free Report) saw a large drop in short interest in February. As of February 15th, there was short interest totalling 17,700 shares, a drop of 66.9% from the January 31st total of 53,500 shares. Based on an average daily trading volume, of 123,500 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.5% of the shares of the company are short sold.
NuCana Price Performance
NASDAQ NCNA traded up $0.04 during trading hours on Friday, hitting $0.97. The company’s stock had a trading volume of 25,621 shares, compared to its average volume of 74,765. NuCana has a 12 month low of $0.85 and a 12 month high of $19.41. The company has a market cap of $2.56 million, a P/E ratio of -0.09 and a beta of 0.96. The company’s 50 day simple moving average is $1.09 and its two-hundred day simple moving average is $2.09.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Two Sigma Securities LLC bought a new position in shares of NuCana during the 4th quarter valued at approximately $25,000. Citadel Advisors LLC bought a new position in shares of NuCana during the 4th quarter valued at approximately $30,000. Virtu Financial LLC bought a new position in shares of NuCana during the 4th quarter valued at approximately $48,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of NuCana during the 4th quarter valued at approximately $54,000. 44.00% of the stock is currently owned by institutional investors.
NuCana Company Profile
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.
Featured Articles
- Five stocks we like better than NuCana
- What is the Dogs of the Dow Strategy? Overview and Examples
- Chaos and Cash: Finding Opportunity in Volatility
- What Are Dividend Challengers?
- Realty Income: An Anchor in Volatile Markets
- What is Put Option Volume?
- Autodesk Designs Value for Investors: Uptrend Set to Continue
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.
